Role of Montelukast in Preventing Relapse in Childhood Idiopathic Nephrotic Syndrome

• Status: Completed
• Trial end date: 2020-05-30
• Target enrollment: 0
• Participant gender: All

Summary

The investigators planned this research to elucidate if there is any efficacy of montelukast, a leukotriene receptor antagonist, in steroid sensitive childhood onset NS to help prevent relapses. This study was done to know the role of leukotriene receptor antagonist (LTRA) montelukast in preventing relapses in idiopathic childhood nephrotic syndrome (NS)

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nishtar Medical University
• Treatments: Montelukast

Criteria

Inclusion Criteria:A total of 106 children aged 1-10 years with idiopathic nephrotic syndrome were enrolled

-

Exclusion Criteria: - Patients having Steroid resistant nephrotic syndrome (SRNS) or those having nephrotic syndrome with atypical features or Secondary cause were excluded.